Preliminary data from the phase 1 trial of ENTR-601-44 targeting DMD exon 44 (ENTR-601-44-101) in healthy volunteers suggested that the drug is safe, with exon skipping levels of up to 0.65% reported (Entrada therapeutics|Entrada therapeutics reports positive preliminary data in healthy volunteers from phase 1 ENTR-601-44-101 trial for Duchenne muscular dystrophy Available from: https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-reports-positive-preliminary-data-healthy). This evidence concerns the gene DMD and Duchenne muscular dystrophy.